Ardena continues M&A strategy with CMO buy

By Flora Southey contact

- Last updated on GMT

(Image: Getty/mikdam)
(Image: Getty/mikdam)
CDMO Ardena has added drug product capabilities with the purchase of active pharmaceutical ingredient and excipient-focused Syntagon.

The acquisition enables the contract manufacturing and development organisation (CDMO) to handle larger batch sizes up to 100kg, adding a manufacturing facility in Södertälje, Sweden, and development and quality control (QC) laboratory in Riga, Latvia, to its site network.

Syntagon’s 30 employees and client portfolio will also be transferred to Ardena.

According to Ardena CEO Harry Christiaens, the firm’s Syntagon acquisition is in line with the its M&A strategy.

Ardena – which launched​ in September 2017 – is the product of a merger between Belgium-based Pharmavize, Dutch firm Crystallics, and Analytical Biochemical Laboratory (ABL) in The Netherlands.

And in March this year, the CDMO bought​ Dutch active pharmaceutical ingredient (API) maker ChemConnection.

Ardena is focused on building a “complementary service portfolio that spans the clinical supply chain from molecule to clinic,” ​Christiaens told us.

Services include chemical-pharmaceutical development and manufacturing services, analytical and bioanalytical support, and regulatory dossier development support, he added.

The acquisition marks the CDMO’s first outside of the Benelux region.

In Scandinavia, Ardena will be “well positioned to capitalise on the emerging biotech segment and broader pharmaceutical market,” ​the CEO said in a statement.

Related news

Related products

show more

Eastern & Western Manufacturing Solutions

Eastern & Western Manufacturing Solutions

Piramal Pharma Solutions | 07-Dec-2021 | Technical / White Paper

The best manufacturing site for a product can change throughout the life cycle. When bringing new drugs to market, biopharma companies may benefit from...

A Culture of Innovation as a Differentiation

A Culture of Innovation as a Differentiation

Softigel by Procaps | 06-Dec-2021 | Product Presentation

We create safe, effective and differentiated pharmaceutical solutions and this has been our goal since day 1. The main driver of our growth is innovation...

Flexibility and capability in pre-filled syringes

Flexibility and capability in pre-filled syringes

Curia | 15-Nov-2021 | Technical / White Paper

Pre-filled syringes have risen in popularity in recent years but the pandemic’s impact on drug development, manufacturing and patient care has created...

Related suppliers

Follow us


View more